Animal studies have shown that XFZY can reduce intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), thereby reducing the inflammatory response induced by ischemia-reperfusion injury (IRI) [13]. The gene discussed is VCAM1; the disease is ischemia reperfusion injury.